Friends of Cancer Research 2019 Annual Meeting | Friends of Cancer Research

You are here

Friends of Cancer Research 2019 Annual Meeting

 

Tuesday, November 12, 2019
8:00AM - 4:00PM
The Willard
1401 Pennsylvania Ave NW

 

Thank you to all that attended! We look forward to seeing everyone next year. As panel slides and white papers are finalized, we will make them available here.


Panel 1 White Paper

Panel 2 White Paper

Panel 3 White Paper


Check back soon for a recap on our Engaging Innovation blog.

 

Friends of Cancer Research (Friends) is proud to host our Annual Meeting to address critical issues in the development of new oncology drugs and diagnostics. This meeting brings together leaders in cancer drug development, federal health and regulatory agencies, academic research, the private sector, and patient advocates for focused discussions on key issues surrounding the development and regulation of cancer drugs and therapies.

 

This year's meeting features panels and experts that will propose unique approaches toward the following vital topics in drug development:

  • Characterizing the Use of External Comparators for Augmenting Randomized Control Arms and Confirming Benefit
  • Data Generation (and Review Considerations) for Use of a Companion Diagnostic for a Group of Oncology Therapeutic Products
  • Immuno-Oncology Combination Drug Development for Patients with Relapsed/Refractory Disease After Initial PD-(L)1 Therapy

Final Agenda

8:00 AM – Registration and Breakfast

 

8:30 AM – Welcome

  • Ellen Sigal, Chairperson & Founder, Friends of Cancer Research
  • Jeff Allen, President & CEO, Friends of Cancer Research

 

8:45 AM – Panel 1: Characterizing the Use of External Controls for Augmenting Randomized Control Arms and Confirming Benefit

  • Moderator: Gary Rosner, Johns Hopkins University
  • Bill Capra, Genentech
  • Ruthie Davi, Acorn AI, a Medidata Company
  • Bindu Kanapuru, FDA
  • Erik Pulkstenis, AbbVie
  • Jeremy Rassen, Aetion
  • Dirk Reitsma, PPD
  • Meghna Samant, Flatiron Health

 

10:30 AM – Break

 

10:45 AM – Panel 2: Immuno-Oncology Drug Development for Patients with Disease Progression After Initial anti-PD-(L)1 Therapy

  • Moderator: Ryan Sullivan, Massachusetts General Hospital
  • Eric Rubin, Merck
  • T.J. Sharpe, Patient Advocate
  • Marc Theoret, FDA
  • Maurizio Voi, Novartis

 

12:30 PM – Lunch


1:00 PM – Lunch Keynote Conversation: Project Orbis

  • Moderator: Richard Pazdur, FDA
  • Shaily Arora, FDA
  • Sanjeeve Bala, FDA
  • Jaigi Mathai, Health Canada
  • Susan Mayer, Eisai
  • Kelly Robinson, Health Canada
  • Bradley Scott, Health Canada
  • Sunita Zalani, Merck

 

2:00 PM - Break
 

2:15 PM – Panel 3: Data Generation (and Review Considerations) for Use of a Companion Diagnostic for a Group of Oncology Therapeutic Products

  • Moderator: Steffan Ho, Pfizer
  • Andrea Ferris, LUNGevity
  • David Hyman, Memorial Sloan Kettering Cancer Center
  • Lynne McBride, Thermo Fisher Scientific
  • Preeti Narayan, FDA
  • Reena Philip, FDA
  • Lakshman Ramamurthy, GlaxoSmithKline

 

4:00 PM – Closing Remarks

  • Jeff Allen, Friends of Cancer Research


For more information or to RSVP, click the link above or contact Heather Chaney at hchaney@focr.org or (202) 944-6719. Check back soon for the final agenda.

Date: 
Tuesday, November 12, 2019 -
8:00am to 4:00pm
Event Type: